At Isomorphic Labs, we collaborate with various companies to generate proprietary data, which has proven to be impactful in drug development.

Our sister company, Isomorphic Labs, is developing technologies around AlphaFold to design drug compounds that bind to specific parts of protein surfaces, which is crucial for understanding diseases.

Many team members at Isomorphic Labs come from non-traditional backgrounds, which allows for fresh perspectives and innovative problem-solving.

We aim to create a general drug design engine with AI that can be applied across various disease areas, not just targeting a single indication.

Our internal drug design projects focus on immunology and oncology, and we've made significant progress using advanced models.

By 2050, we envision a fully automated lab capable of simulating drug interactions with high accuracy, significantly speeding up drug discovery processes.

To achieve transformative drug design, we need several more breakthroughs similar to AlphaFold, focusing on different core concepts of biology and chemistry.

Our goal is to solve all diseases by leveraging AI to transform our understanding of biology and chemistry, enabling us to manipulate and craft solutions effectively.

Drug design is complex, with numerous bottlenecks before reaching clinical trials, and we need to innovate in this space to improve the process.